Evaluation of Medication Adherence and Rescue Medication Use in Non-Exacerbating Patients with COPD Receiving Umeclidinium/Vilanterol or Budesonide/Formoterol as Initial Maintenance Therapy

References

• Global initiative for chronic obstructive lung disease (GOLD). Global Strategy Diagnosis, Management, Prevention Chronic Obstructive Pulmonary Disease. 2020 Available from: https://goldcopd.org/gold-reports/. Accessed August, 2020.
   Google Scholar
• WallaceAE, KailaS, BayerV, et al. Health care resource utilization and exacerbation rates in patients with COPD stratified by disease severity in a commercially insured population. J Manag Care Spec Pharm. 2019;25(2):205–217. doi:10.18553/jmcp.2019.25.2.20530698096
   PubMed Web of Science ®Google Scholar
• RestrepoRD, AlvarezMT, WittnebelLD, et al. Medication adherence issues in patients treated for COPD. Int J COPD. 2008;3(3):371–384. doi:10.2147/COPD.S3036
   Google Scholar
• ManninoDM, YuT-C, ZhouH, HiguchiK. Effects of GOLD-adherent prescribing on COPD symptom burden, exacerbations, and health care utilization in a real-world setting. COPD. 2015;2(3):223–235. doi:10.15326/jcopdf.2.3.2014.015128848845
   PubMedGoogle Scholar
• DavisJR, WuB, KernDM, et al. Impact of nonadherence to inhaled corticosteroid/LABA therapy on COPD exacerbation rates and healthcare costs in a commercially insured US population. Am Drug Health Benefits. 2017;10(2):91–102.
   Web of Science ®Google Scholar
• MakelaMJ, BackerV, HedegaardM, LarssonK. Adherence to inhaled therapies, health outcomes and costs in patients with asthma and COPD. Respir Med. 2013;107(10):1481–1490. doi:10.1016/j.rmed.2013.04.00523643487
   PubMed Web of Science ®Google Scholar
• ToyEL, BeaulieuNU, McHaleJM, et al. Treatment of COPD: relationships between daily dosing frequency, adherence, resource use, and costs. Respir Med. 2011;105(3):435–441. doi:10.1016/j.rmed.2010.09.00620880687
   PubMed Web of Science ®Google Scholar
• PunekarYS, SharmaS, PahwaA, TakyarJ, NayaI, JonesPW. Rescue medication use as a patient-reported outcome in COPD: a systematic review and regression analysis. Respir Res. 2017;18(1):86. doi:10.1186/s12931-017-0566-128482883
   PubMed Web of Science ®Google Scholar
• FanVS, Gylys-ColwellI, LockeE, et al. Overuse of short-acting beta-agonist bronchodilators in COPD during periods of clinical stability. Respir Med. 2016;116:100–106. doi:10.1016/j.rmed.2016.05.01127296828
   PubMed Web of Science ®Google Scholar
• StanfordRH, NagA, MapelDW, et al. Validation of a new risk measure for chronic obstructive pulmonary disease exacerbation using health insurance claims data. Ann Am Thorac Soc. 2016;13(7):1067–1075. doi:10.1513/AnnalsATS.201508-493OC27070274
   PubMed Web of Science ®Google Scholar
• JenkinsCR, PostmaDS, AnzuetoAR, et al. Reliever salbutamol use as a measure of exacerbation risk in chronic obstructive pulmonary disease. BMC Pulm Med. 2015;15:97. doi:10.1186/s12890-015-0077-026293575
   PubMed Web of Science ®Google Scholar
• Simoni-WastilaL, WeiYJ, QianJ, et al. Association of chronic obstructive pulmonary disease maintenance medication adherence with all-cause hospitalization and spending in a Medicare population. Am J Geriatr Pharmacother. 2012;10(3):201–210. doi:10.1016/j.amjopharm.2012.04.00222521808
   PubMedGoogle Scholar
• VestboJ, AndersonJA, CalverleyPM, et al. Adherence to inhaled therapy, mortality and hospital admission in COPD. Thorax. 2009;64(11):939–943. doi:10.1136/thx.2009.11366219703830
   PubMed Web of Science ®Google Scholar
• LeidyNK, SextonCC, JonesPW, et al. Measuring respiratory symptoms in clinical trials of COPD: reliability and validity of a daily diary. Thorax. 2014;69(5):443–449. doi:10.1136/thoraxjnl-2013-20442824595666
   PubMed Web of Science ®Google Scholar
• MoretzC, SharpstenL, BengtsonLG, et al. Real-world effectiveness of umeclidinium/vilanterol versus fluticasone propionate/salmeterol as initial maintenance therapy for chronic obstructive pulmonary disease (COPD): a retrospective cohort study. Int J Chron Obstruct Pulmon Dis. 2019;14:1721–1737. doi:10.2147/COPD.S20464931534326
   PubMed Web of Science ®Google Scholar
• CasasA, Montes de OcaM, MenezesAM, et al. Respiratory medication used in COPD patients from seven Latin American countries: the LASSYC study. Int J Chron Obstruct Pulmon Dis. 2018;13:1545–1556. doi:10.2147/COPD.S15409729785104
   PubMed Web of Science ®Google Scholar
• RodrigoGJ, PriceD, AnzuetoA, et al. LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis. Int J Chron Obstruct Pulmon Dis. 2017;12:907–922. doi:10.2147/COPD.S13048228360514
   PubMed Web of Science ®Google Scholar
• RoglianiP, CalzettaL, BraidoF, et al. LABA/LAMA fixed-dose combinations in patients with COPD: a systematic review. Int J Chron Obstruct Pulmon Dis. 2018;13:3115–3130. doi:10.2147/COPD.S17060630323582
   PubMed Web of Science ®Google Scholar
• VogelmeierCF, GagaM, Aalamian-MattheisM, et al. Efficacy and safety of direct switch to indacaterol/glycopyrronium in patients with moderate COPD: the CRYSTAL open-label randomised trial. Respir Res. 2017;18(1):140. doi:10.1186/s12931-017-0622-x28720132
   PubMed Web of Science ®Google Scholar
• WedzichaJA, BanerjiD, ChapmanKR, et al. Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD. N Engl J Med. 2016;374(23):2222–2234. doi:10.1056/NEJMoa151638527181606
   PubMed Web of Science ®Google Scholar
• MoretzC, BengtsonLG, SharpstenL, et al. Evaluation of rescue medication use and medication adherence receiving umeclidinium/vilanterol versus tiotropium bromide/olodaterol. Int J Chron Obstruct Pulmon Dis. 2019;14:2047–2060. doi:10.2147/COPD.S21352031564852
   PubMed Web of Science ®Google Scholar
• FeldmanGJ, SousaAR, LipsonDA, et al. Comparative efficacy of once-daily umeclidinium/vilanterol and tiotropium/olodaterol therapy in symptomatic chronic obstructive pulmonary disease: a randomized study. Adv Ther. 2017;34:2518–2533. doi:10.1007/s12325-017-0626-429094315
   PubMed Web of Science ®Google Scholar